Dialkyl Carbamoyl Chloride: A Hopeful Ally in Fighting Inflammation and Encouraging Healing in Diabetic Ulcers

Background: Diabetic foot ulcers (DFUs) are a serious complication of diabetes mellitus, often difficult to heal due to chronic inflammation, impaired blood flow, and infection risk. Advanced wound care strategies, including antimicrobial dressings, are essential. Dialkyl carbamoyl chloride (DACC)-coated dressings bind and remove bacteria, potentially reducing inflammation and enhancing tissue repair. Using a Wistar rat model, the current study aimed to evaluate the effects of DACC on inflammation and tissue regeneration in diabetic ulcers.Methods: An experimental study was conducted on 27 Wistar rats with diabetes induced by streptozotocin–nicotinamide divided into three groups: control, saline-treated, and DACC-treated. Full-thickness skin wounds were created and treated for 14 days. We assessed inflammatory markers (interleukin-6, macrophage count, degree of inflammation), angiogenesis, fibroblast proliferation, and collagen deposition using histological analysis and enzyme-linked immunosorbent assay. Statistical analysis included analysis of variance and Kruskal-Wallis tests.Results: The DACC-treated group showed significantly lower IL-6 levels, macrophage infiltration, and inflammation compared to the control and saline groups (P<0.05). Although angiogenesis and fibroblast activity were most pronounced in the saline group, DACC treatment led to the greatest increase in collagen deposition.Conclusion: DACC dressings effectively reduce inflammation and enhance collagen formation in diabetic wounds, indicating promise as a wound healing agent. Further research is warranted to explore its long-term impact on angiogenesis and fibroblast proliferation.